Author/Authors :
He, Yong Department of Thoracic Surgery, China , Jiang, Zhenjie Department of Thoracic Surgery, China , Tong, Fengzhi Clinical Laboratory, China , Li, Mingwu Department of Thoracic Surgery, China , Yin, Xingru Department of Thoracic Surgery, China , Hu, Shixin Department of Thoracic Surgery, China , Wang, Linlin Department of Thoracic Surgery, China
Abstract :
Purpose:
To evaluate the possibility of using peripheral-blood presurfactant protein B (Pro-SFTPB) for screening non-small cell lung cancer (NSCLC).
Methods:
A total of 873 healthy volunteers and 165 lung cancer patients hospitalized in the Fifth People’s Hospital of Dalian were tested Pro-SFTPB once every half year from January 2014 to September 2015. The healthy volunteers were also conducted spiral computed tomography (CT) examination once every year. The data were then com-pared and statistically analyzed.
Results:
The positive expression rate of Pro-SFTPB in NSCLC was significantly higher than that in healthy volunteers, and significantly higher in lung adenocarcinoma than in squamous cell carcinoma; additionally, the expression rate was increased with the in-crease of smoking index, and the intergroup differences showed statistical signifi-cance (p≤0.05). The positive rate of newly diagnosed lung cancer was 29.55%, higher than healthy volunteers (22.34%), but there was no significant difference (p>0.05).
Conclusion:
Pro-SFTPB is over expressed in non-small cell lung cancer, especially in lung adeno-carcinoma, but it can’t be used as a clinical screening tool for lung cancer.
